TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04769323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
Study: NCT04845919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Aminolevulinic Acid
Description: SDT treatment with 5-ALA using the ExAblate Model 4000 Type-2 Neuro-System.
Study: NCT04769323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional home exercises
Description: Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional home exercises
Description: Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
Study: NCT05562193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention coupled with standard post-cancer directed treatment care
Description: CCS will participate in a 16-week physical activity program. CCS will be instructed to start with a session duration of \<15-min, three days per week at low intensity (e.g., activities expending \>1.5 to 3 METs or intensity \<5 on a scale of 0 to 10). Any type of physical activity will be acceptable. The program will be individualized, and activity increased according to patients' health status, results from the physical function assessment, and most recent week's achieved physical activities. The program will include support calls and texts from research staff (exercise physiologist). The program will be modified and adapted during support calls or texts, including frequency, intensity, time and type to maximize CCS' success. CCS will receive a Fitbit at the beginning of the intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard post-cancer directed treatment care control
Description: CCS in the control group will not participate in a 16-week physical activity program and will not receive support calls or texts. Physical activity advice according to the Children's Oncology Group Guidelines for Diet and Physical Activity recommendations and the International Pediatric Oncology Exercise Guidelines will be offered to CCS following completion of 16-week follow-up. Moreover, CCS will receive a Fitbit following completion of 16-week follow-up
Study: NCT05966402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Immersion in Virtual Reality
Study: NCT04305691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05139602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous Injection
Study: NCT05596084

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maxillary sinus augmentation and implant placement
Description: For maxillary sinus augmentation, the area will be prepared by lifting a full-thickness flap. The sinus membrane will be carefully elevated by opening a window through the lateral wall of the sinus on both sides.platelet-rich fibrin prepared with titanium on the other side will be placed in the space prepared in the sinus region by random selection. For Platelet-rich fibrin prepared with titanium (T-PRF), the blood taken from the patient to a 20 cc injektor was put into titanium tubes and prepared by centrifugation at 2700 rpm for 14 minutes according to the standard protocol. Then, 6 months after the surgery, histological sample will be taken with a trephine bur in both groups and the implant will be placed in accordance with the standard protocol. The stability value (ISQ) of the placed implant will be measured with the Ostell device at the time the implant is placed and 3 months after it is placed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus augmentation with bovine bone graft
Description: For maxillary sinus augmentation, the area will be prepared by lifting a full-thickness flap. The sinus membrane will be carefully elevated by opening a window through the lateral wall of the sinus on both sides. Bio-oss bovine bone graft on one side will be placed in the space prepared in the sinus region by random selection. For Platelet-rich fibrin prepared, the blood taken from the patient to a 20 cc injektor was put into titanium tubes and prepared by centrifugation at 2700 rpm for 13 minutes according to the standard protocol. Then, 6 months after the surgery, histological sample will be taken with a trephine bur in both groups and the implant will be placed in accordance with the standard protocol. The stability value (ISQ) of the placed implant will be measured with the Ostell device at the time the implant is placed and 3 months after it is placed.
Study: NCT05445154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKLB1028 Dose Escalation
Description: Drug :SKLB1028 ;Drug: Cytarabine ;Drug: Daunorubicin
Study: NCT05067439

Intervention type: DRUG
Group type: OTHER
Intervention: Abrocitinib
Description: 200 mg once daily (QD)

Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole
Description: single doses of 10 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole
Description: single doses of 10 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Caffeine
Description: single dose of 100 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Caffeine
Description: single dose of 100 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Efavirenz
Description: single doses of 50 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Efavirenz
Description: single doses of 50 mg
Study: NCT06373484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training
Description: Two 15-session multi-component cognitive-behavioral group treatments for children with disruptive behavior and their parents (i.e., one program for children aged 6-8 years and their parents and another for children aged 9-12 years and their parents. The programs have a child and parent group that are implemented concurrently).
Study: NCT06228521

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liquid nitrogen sprayed
Description: Liquid nitrogen sprayed on each wart using a standardised technique. Freeze-thaw cycle repeated up to 3 times per wart per session. 4 sessions at weekly intervals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 980nm diode laser applied
Description: 980nm diode laser applied to each wart for 5 seconds at 2W power and 1mm spot size. 4 sessions at weekly intervals.
Study: NCT06267456

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Upper Limb Rotation Test
Description: The athlete is positioned with the shoulder, elbow lateral epicondyle, greater trochanter, and ankle lateral malleolus in contact with the wall. In the push-up position, the elbows are started at shoulder height with a 90° bend, and the feet are placed in a shoulder-width apart position. Athletes are instructed to perform a rotation of the shoulder and trunk by touching a vertically placed band on the wall for 15 seconds in the position of 90° abduction and 90° external rotation of the shoulder. The tested side is the upper extremity where the closed kinetic chain position is maintained.
Study: NCT05433311

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Neutral position training, transversus abdominis/multifidius/abdominal/back extensors strengthening exercise, bridge exercise, cat-camel exercise, lumbal extensor/hamstring/gastrosoleus/latissimus dorsi/gluteal stretching exercises
Study: NCT06052345

Intervention type: DEVICE
Intervention: Garmin smartwatch
Description: * Physical activity (Activity sessions, type and length of activity, activity intensity estimations)~* Meal detection and meal characteristics (accelerometry and gyroscope data)~* Oxygen saturation (pulse oximetry)~* Number of steps (pedometer)~* Stress level indicators (based on heart-rate analytics)~* Sleep patterns (sleep and wake-up time, sleep quality)

Intervention type: DEVICE
Intervention: Garmin smartwatch
Description: * Physical activity (Activity sessions, type and length of activity, activity intensity estimations)~* Meal detection and meal characteristics (accelerometry and gyroscope data)~* Oxygen saturation (pulse oximetry)~* Number of steps (pedometer)~* Stress level indicators (based on heart-rate analytics)~* Sleep patterns (sleep and wake-up time, sleep quality)

Intervention type: OTHER
Intervention: REBECCA Mobile application
Description: * GPS positioning (daily location change patterns through pathway analysis and Point-of-interest analysis based on type-of-location automatic detection)~* Self-reports from patients and companions reports on mental and physical health, as well as periodic quality of life evaluations3~* Patient self-uploaded pictures of meals (for evaluation of nutritional habits) and living environment stressors (for evaluation of living environment and self-perceived stressor analysis)

Intervention type: OTHER
Intervention: REBECCA Mobile application
Description: * GPS positioning (daily location change patterns through pathway analysis and Point-of-interest analysis based on type-of-location automatic detection)~* Self-reports from patients and companions reports on mental and physical health, as well as periodic quality of life evaluations3~* Patient self-uploaded pictures of meals (for evaluation of nutritional habits) and living environment stressors (for evaluation of living environment and self-perceived stressor analysis)

Intervention type: OTHER
Intervention: REBECCA PC plug-in
Description: * the developed plug-in monitors online activity, collecting anonymized data from web-browsers (Chrome) and social media (Facebook, Youtube and Instagram).~* These are relevant to current and historical data on: i) keywords in searches, ii) types of websites visited, iii) reactions to posts, iv) participation in online groups, v) types of bookmarked websites
Study: NCT05139602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection
Study: NCT05204927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-I&T
Description: Radioligand therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone with Prednisone or Enzalutamide
Description: Hormone Therapy
Study: NCT05382091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone implant
Description: 3.6 g per implant set each containing 60% naltrexone
Study: NCT04349059

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Animal based diet
Description: Food will be provided by Montefiore-Einstein Food Services

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant based diet
Description: Food will be provided by Montefiore-Einstein Food Services
Study: NCT05474170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AHA resuscitation sequence
Description: Starting the cardiopulmonary resuscitation by following the AHA guideline, meaning starting with 15 chest compressions, followed by 2 ventilations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AHA resuscitation sequence
Description: Starting the cardiopulmonary resuscitation by following the AHA guideline, meaning starting with 15 chest compressions, followed by 2 ventilations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERC resuscitation sequence
Description: Starting the cardiopulmonary resuscitation by following the ERC guideline, meaning starting with 5 initial ventilations, then alternating 15 chest compressions with 2 ventilations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERC resuscitation sequence
Description: Starting the cardiopulmonary resuscitation by following the ERC guideline, meaning starting with 5 initial ventilations, then alternating 15 chest compressions with 2 ventilations
Study: NCT05274854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing
Description: Pre consultation interventions consist of one of four intervention a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a) consultant-led outpatient clinic or b) a integrated care clinic
Description: Consultation intervention consists of one of two interventions a) consultant-led outpatient clinic or b) a integrated care clinic
Study: NCT06648200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS004
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: Specified dose on specified days.
Study: NCT04893447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPI+
Description: Suicide prevention hotline follow-up specialists will call participants to (1) conduct a brief suicide risk assessment; (2) review and discuss the participant's connection and support plan or safety plan; and (3) provide referrals to social services or other support with treatment engagement, if indicated. Participants will receive at least one and optional additional phone calls, generally delivered according to the following schedule: days 3, 7, 14, 30, 60, 90. Modifications may be made to the schedule due to weekends, holidays, or participant availability, and additional calls may be scheduled as desired by the participant. The follow-up will stop once the participant is successfully engaged in outpatient treatment or does not desire further follow-up support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SP+CC (Caring Contacts)
Description: SP+CC follow-up includes one phone conversation with a suicide prevention hotline follow-up specialist and a series of personalized caring messages sent over the course of 12 months via text or email (based on participant preference). Caring contacts will generally be sent according to the following schedule: 3 in the first week, 6 weekly, 6 bi-weekly, 4 monthly; 2 bi-monthly, and one each for the participant's birthday, Thanksgiving, Christmas, and New Year's (total of 25 over 12 months). Slight variation in the schedule is allowed. There is no expectation that participants respond to the text messages; if they do, follow-up specialists reply to any incoming texts. Replies are individually-tailored and caring.
Study: NCT06289478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid administration
Description: Tranexamic acid will be topically administered in intervention groups

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical tranexamic acid administration
Description: Tranexamic acid will be topically administered in intervention groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid administration
Description: Tranexamic acid will be topically administered in intervention groups
Study: NCT06288360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200 mg, intravenously, 20-60 min. 2 times, every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: 260 mg/m² over 30 min, 3 times, every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 4 h, 75-80 mg/m², 3 times, every 21 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical surgery
Description: Radical hysterectomy + pelvic lymphadenectomy 士 para-aortic lymphadenectomy
Study: NCT06070181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivate
Description: 'Applying Enamel matrix derivate in the periodontal pockets after completing the non-surgical periodontal treatment

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-surgical periodontal treatment
Description: No additional/adjunctive treatment with Emdogain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: No additional/adjunctive treatment with Emdogain
Study: NCT05406115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 786
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 786
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 786
Description: Oral tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet
Study: NCT05066204

Intervention type: OTHER
Group type: OTHER
Intervention: Sequence of teaching-/learningmethod
Description: see: arm/group descriptions

Intervention type: OTHER
Group type: OTHER
Intervention: Sequence of teaching-/learningmethod
Description: see: arm/group descriptions
Study: NCT05754762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Advanced intravenous injection of remifentanil before the etomidate injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Advanced intravenous injection of remifentanil before the etomidate injection
Study: NCT06267456

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Upper Limb Rotation Test
Description: The athlete is positioned with the shoulder, elbow lateral epicondyle, greater trochanter, and ankle lateral malleolus in contact with the wall. In the push-up position, the elbows are started at shoulder height with a 90° bend, and the feet are placed in a shoulder-width apart position. Athletes are instructed to perform a rotation of the shoulder and trunk by touching a vertically placed band on the wall for 15 seconds in the position of 90° abduction and 90° external rotation of the shoulder. The tested side is the upper extremity where the closed kinetic chain position is maintained.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Upper Limb Rotation Test
Description: The athlete is positioned with the shoulder, elbow lateral epicondyle, greater trochanter, and ankle lateral malleolus in contact with the wall. In the push-up position, the elbows are started at shoulder height with a 90° bend, and the feet are placed in a shoulder-width apart position. Athletes are instructed to perform a rotation of the shoulder and trunk by touching a vertically placed band on the wall for 15 seconds in the position of 90° abduction and 90° external rotation of the shoulder. The tested side is the upper extremity where the closed kinetic chain position is maintained.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Closed Kinetic Chain Upper Extremity Stability Test
Description: Athletes were placed in a push-up position with a distance of 91.44 centimeters (cm) (3 feet) between their hands for the test position. Subsequently, they were instructed to touch one hand to the other as quickly as possible. The total number of touches within a 15-second period was recorded. Modified push-up position was used for women, and regular push-up position for men during this time. Prior to the test, a familiarization trial consisting of 5 repetitions was performed. The test was then repeated 3 times, and the average of these repetitions was recorded as the score. Individuals were given a 45-second rest period between repetitions. The normalized score, representing the touch count per individual's height, was calculated. The power score was obtained by multiplying the touch count by 68% of the individual's body weight in kilograms.
Study: NCT05754762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Advanced intravenous injection of remifentanil before the etomidate injection
Study: NCT06274879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabin, Cisplatin and Durvalumab
Description: CICI (Gemcitabin d1 \& d8 Cisplatin d1 \& d8, Durvalumab d1) are administered repeating every 21 days for a total of 8 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabin, Cisplatin and Durvalumab
Description: CICI (Gemcitabin d1 \& d8 Cisplatin d1 \& d8, Durvalumab d1) are administered repeating every 21 days for a total of 8 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biliary Radiofrequency Ablation
Description: Biliary Radiofrequency Ablation is applied at baseline, 6 and 12 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Retrograde Cholangio-Pancreatography with stenting
Description: ERCP with stenting are applied at baseline and as clinically indicated

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Retrograde Cholangio-Pancreatography with stenting
Description: ERCP with stenting are applied at baseline and as clinically indicated
Study: NCT06496191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: - Single dose (30gm/90ml) of FMT will be given via upper GI gastroduodenoscope at D4

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMT
Description: Baclofen + AUD counselling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMT
Description: Baclofen + AUD counselling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo identical to the FMT arm.
Study: NCT05628805

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iTBS
Description: intermittent theta burst stimulation with TMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: intermittent theta burst stimulation with TMS